HDAC3 and cancer: Their favorablepharmacokinetic profiles and tunable selectivity hold promise fortargeting isoforms linked to cancer, chronic inflammatory disorders,and immunomodulation, such as HDAC3’s role in PD-L1 expression.Additionally, their utility has also been proven in developing PROTAC-basedderivatives, in which selective HDAC3 or HDAC8 degradation has beenachieved.−, ,